FOXO4-DRI vs Rapamycin
A side-by-side research comparison of FOXO4-DRI and Rapamycin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Rapamycin |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Rapamycin (Sirolimus) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. |
| Molecular weight | ~4,500 Da | 914.17 Da |
| Half-life | 12-24 hours (D-amino acid stability) | ~62 hours |
| Bioavailability | Moderate (SubQ) | ~14% oral |
| Typical dose | 5-10 mg/kg (animal studies) | 3-6 mg |
| Frequency | 3x per week for 3 weeks | Once weekly |
| Route | Subcutaneous | Oral tablet |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
Related comparisons
Research and educational reference only. Not medical advice.